PHILADELPHIA, Feb. 18, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) has received a letter from the Food and Drug Agency (“FDA”) indicating that the originally scheduled Prescription Drug User Fee Act (“PDUFA”) date on the Ampligen(r) (Poly I: Poly C12U) New Drug Application (NDA) would be extended by three months “in order to provide time for a full review of the submission.” Additional data were received by the FDA within 3 months of the user fee goal date.
